Introduced for Gene Therapy Production: A New Medium for Cultivating HEK293 Cells via Perfusion Technique
Fujifilm Biosciences has expanded its portfolio for gene therapy application solutions with the launch of BalanCD HEK293 Perfusion A. This new medium is specifically designed to maximize cell growth, viability, and productivity in gene therapy production. HEK293 cells are well-established for gene therapy applications due to their reliable growth rates, high transfection success, and expression of cellular factors needed for virus replication. BalanCD HEK293 Perfusion A builds upon this foundation, offering a medium suitable for the production of viral vectors such as Adeno-Associated Virus (AAV), lentivirus, and adenovirus. The medium is compatible with different types of transfection methods and supports a range of applications, including viral vector production, transient protein expression, and recombinant protein production. It is also worth noting that AAV and LV are key virus types for in vivo and in vitro gene transfer, as noted by Erik Vaessen, the chief business officer for Fujifilm Biosciences. BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology for scalable production of viral vectors in gene therapy development. This product, designed for high-density perfusion culture, can help reduce overall capital expenditures associated with AAV and LV production. The medium provides clinical-quality, high-performing media that can support large-scale commercial batch sizes for advanced therapy development. It is available in various media package options for continuous processing, making it a valuable tool in the production of viral vectors such as AAV, lentivirus, and adenovirus. The launch of BalanCD HEK293 Perfusion A by Fujifilm Biosciences is significant for the advancement of gene therapy development. These media are critically important and distinct from general-purpose media due to the stringent requirements for safety, yield, and regulatory compliance in gene therapy. BalanCD HEK293 Perfusion A continues to harness the benefits of perfusion technology, offering a solution that is suited for both steady-state and intensified perfusion processes. Furthermore, it can help enable a reduction in overall capital expenditures for AAV and LV production, and maximize resources for consistency and scalability in advanced therapy development. In summary, the introduction of BalanCD HEK293 Perfusion A by Fujifilm Biosciences marks a significant step forward in the field of gene therapy. This medium, designed for high-density perfusion culture, offers a scalable and cost-effective solution for the production of viral vectors, supporting the growth, viability, and productivity of cells used in gene therapy.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
